Oral Vitamin D3 Effect on Inflammatory Biomarkers in Ulcerative Colitis Patients

This randomized controlled trial aims to evaluate the effect of oral vitamin D3 supplementation on inflammatory biomarkers and disease activity in Pakistani patients with moderate ulcerative colitis. Sixty patients will be randomized to receive either standard treatment alone/Placebo or standard treatment plus vitamin D3 (50,000 IU fortnightly) for 12 weeks. Primary outcomes include changes in blood (CRP, ESR, IL-6) and fecal (calprotectin) inflammatory biomarkers, and disease activity assessed by the partial Mayo score. Secondary outcomes include vitamin D status, dietary intake, and quality of life. The study will provide insights into the immune-modulating and anti-inflammatory role of vitamin D3 as an adjunct therapy in ulcerative colitis.

NCT Number	NCT07269223
Lead Sponsor	University of Veterinary and Animal Sciences, Lahore - Pakistan
Conditions	Ulcerative Colitis (UC)
Enrollment	60 participants
Start Date	2025-09-02
Primary Completion	2025-12-15 (estimated)
Study Completion	2025-12-30 (estimated)
Updated on ClinicalTrials.gov	2025-12-17